The Judicial Panel on Multidistrict Litigation (JPML) consolidated 53 cases pending in seven federal district courts involving anti-diabetes incretin-based medications Byetta, Janumet, Januvia, and Victoza into multidistrict litigation (MDL) after a successful argument by Watts Guerra Partner Ryan L. Thompson. The MDL was centralized in the Southern District of California under the name In re Incretin-Based Therapies Products Liability Litigation and assigned to the Honorable Anthony J. Battaglia.
It is uncommon to centralize litigation against multiple competing corporations that market, manufacture, and sell similar products. However, several victims took a combination of Byetta, Janumet, Januvia, and Victoza throughout their diabetic treatment, and all developed pancreatic cancer. Therefore, to avoid duplicating investigative efforts and litigation if each drug’s litigation was handled separately, the cases were consolidated. Multidistrict litigation allows federal courts to resourcefully handle numerous related cases filed in different jurisdictions by conserving funds and streamlining the preliminary litigation phases under one judge.
The incretins pancreatic cancer plaintiffs, hailing from California to Pennsylvania, allege that these diabetes medications manufactured and or marketed by Amylin, Eli Lilly, Merck, and Novo Nordisk caused them or a loved one to develop pancreatic cancer, resulting in death in some cases.
The lawyers of Watts Guerra LLP are handling the largest active docket of incretins cancer cases in the country. We proudly represent hundreds of families across the country, and continue to review potential cases nationwide. If you or a family member used Byetta, Januvia, Victoza, or any other diabetes medication and were diagnosed with pancreatic cancer, contact our firm now to find out how our lawyers can help you and your family.
blog comments powered by Disqus